Retatrutide: Triple Mechanism That Changes Weight Loss Rules

Imagine three loudspeakers in your head constantly shouting "eat more". Ozempic turns off one. Mounjaro turns off two. But what if you could turn off all three at once?

This is exactly what Retatrutide does - a molecule that, for the first time in history, activates three receptors simultaneously. And the results amaze even researchers.

What is Retatrutide and why is everyone talking about it?

Retatrutide (code LY3437943) is an experimental molecule from Eli Lilly that represents a new generation of metabolic drugs [4]. Unlike Ozempic, which works on one receptor, and Mounjaro, which activates two, Retatrutide combines three signals in one molecule: GLP-1, GIP and glucagon [5].

It is administered once weekly by subcutaneous injection. No daily pills, no constant reminders.

The first Phase 2 results were published in the New England Journal of Medicine in 2023. And they exceeded all expectations: participants on the maximum dose lost over 24% of their initial weight [2].

Triple mechanism - why are three receptors better than two?

To understand why Retatrutide is so effective, we need to understand what each of the three receptors does.

It's the glucagon receptor that makes Retatrutide unique. Researchers from Lola Health explain: adding the glucagon receptor "unlocks effects that neither semaglutide nor tirzepatide can achieve - especially in reducing liver fat and overall metabolic improvement" [5].

If Mounjaro is an evolution from Ozempic, then Retatrutide is the next step in this evolution [5].

Phase 2 results - how many kilograms do people actually lose?

In June 2023, Eli Lilly announced Phase 2 study results that immediately made it to the New England Journal of Medicine [2].

On the maximum dose, the average loss was 57.8 pounds (26.2 kg) [2]. By the way, already at 24 weeks participants lost up to 17.5% of weight - and then the result continued to improve [2].

Important clarification. The TRIUMPH-4 study (Phase 3) has already shown results up to 28.7% weight loss at 68 weeks [5]. This exceeds even the Phase 2 results.

But there's a nuance. Phase 2 had 338 participants, while Mounjaro Phase 3 studies covered over 2500 people [4]. A larger sample size may yield somewhat different results. We're waiting for full TRIUMPH data.

What is certain: in direct comparison, tirzepatide beat semaglutide by 47% in the SURMOUNT-5 study [5]. And Retatrutide shows even better numbers.

Retatrutide side effects - what to expect?

The most common side effects are gastrointestinal. This is logical: the GLP-1 receptor affects the digestive system.

An interesting finding from Phase 3: dysesthesia (tingling, altered skin sensation) was recorded in 20.9% of participants on 12 mg. Researchers link this specifically to glucagon receptor activity [1].

They also noticed an increase in heart rate by 5-10 beats per minute, peaking at 24 weeks and decreasing thereafter [1].

But here's the good news: serious side effects occurred with equal frequency in the Retatrutide and placebo groups — 4% in each [1]. Overall, the safety profile is similar to Mounjaro [3].

Where Phase 3 stands now - the TRIUMPH program

Eli Lilly has launched a large-scale research program called TRIUMPH. It includes several separate trials:

• TRIUMPH-1: people with obesity without diabetes
• TRIUMPH-2: obesity combined with type 2 diabetes
• TRIUMPH-3: direct comparison with Zepbound (tirzepatide) [4]

Phase 1 began in 2021 to establish safe doses. Phase 2 with publication in NEJM - 2023. Large-scale Phase 3 trials are ongoing worldwide [4].

Expected results: 2026-2027. FDA submission for approval - approximately the same period [4].

How to try Retatrutide in Ukraine

Since original Retatrutide from Eli Lilly has not yet reached the market (Phase 3 continues), research peptides from specialized manufacturers are available in Ukraine.

DOZA is one of the few services in Ukraine where you can get Retatrutide. Manufacturers: ALLUVI Healthcare, SYNEDICA Laboratories (Germany) and PEN PEPTIDE — specialized peptide laboratories.

Cost: from 9,000 UAH. Test dose — from 2,500 UAH. View catalog →

Starting dose: 2.5 mg weekly, with gradual escalation to 5-10 mg under specialist supervision.

Who is Retatrutide suitable for - and who should wait

Retatrutide is not a starting option. Here's why.

Retatrutide is really suitable for those who:

• Have already tried Mounjaro or Ozempic with insufficient results
• Have significant BMI (40+) and need maximum effect
• Are ready for the most powerful tool with understanding of risks

But if you're just starting your journey to your desired figure — it's better to start with Mounjaro 2.5 mg. This way you'll understand how your body reacts to GLP-1, and leave the more powerful options 'for later'.

From DOZA experience: clients who completed the first month on Mounjaro better understand how their body works and tolerate escalation more easily.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for starter dose.
• Buy Retatrutide in Ukraine — new generation triple agonist (GLP-1 + GIP + glucagon) with clinical efficacy of -24% weight loss over 48 weeks.

Where to buy

DOZA supplies the products mentioned in this article with an official cold chain and 24/7 specialist support:

• Buy Mounjaro in Ukraine — DOZA catalog with all 6 doses (2.5–15 mg) and official 24h cold-chain delivery. Current Mounjaro prices.